Robert Nelsen

Insider Reports History

Location: Chicago, IL
Signature: /s/ Ryan Brown, attorney-in-fact
All insider transactions: Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Robert Nelsen:

Form 4 holding Director

Denali Therapeutics Inc.

Security class: Common Stock
Shares / value: 9,668,749
Estimated value: $178,098,357
Report date: 02 Jun 2021
Price: $18.42
Ownership: Held by ARCH Venture Fund VIII, L.P.

Form 4 holding Director, 10%+ Owner

Lyell Immunopharma, Inc.

Security class: Common Stock
Shares / value: 18,206,358
Estimated value: $41,510,496
Report date: 14 Jun 2024
Price: $2.28
Ownership: ARCH Venture Fund IX,L.P.

Form 4 holding Director, 10%+ Owner

Lyell Immunopharma, Inc.

Security class: Common Stock
Shares / value: 18,206,358
Estimated value: $41,510,496
Report date: 14 Jun 2024
Price: $2.28
Ownership: ARCH Venture Fund IX Overage, L.P.

Form 4 holding Director, 10%+ Owner

Prime Medicine, Inc.

Security class: Common Stock
Shares / value: 6,128,297
Estimated value: $26,658,091
Report date: 01 Aug 2025
Price: $4.35
Ownership: By ARCH Venture Fund X, L.P.

Form 4 holding Director, 10%+ Owner

Prime Medicine, Inc.

Security class: Common Stock
Shares / value: 6,128,297
Estimated value: $26,658,091
Report date: 01 Aug 2025
Price: $4.35
Ownership: By ARCH Venture Fund X Overage, L.P.

Form 4 holding Director, 10%+ Owner

Prime Medicine, Inc.

Security class: Common Stock
Shares / value: 6,230,300
Estimated value: $20,559,990
Report date: 01 Aug 2025
Price: $3.30
Ownership: By ARCH Venture Fund XII, L.P.

Form 4 holding Director

Vir Biotechnology, Inc.

Security class: Common Stock
Shares / value: 584,148
Estimated value: $5,524,697
Report date: 30 May 2024
Price: $9.46
Ownership: Direct

Form 4 holding Director

Vir Biotechnology, Inc.

Security class: Common Stock
Shares / value: 33,893
Estimated value: $320,550
Report date: 30 May 2024
Price: $9.46
Ownership: Indirect

Form 4 holding Director

Denali Therapeutics Inc.

Security class: Common Stock
Shares / value: 12,432
Estimated value: $228,997
Report date: 02 Jun 2021
Price: $18.42
Ownership: Direct

Form 4 holding Director, 10%+ Owner

Prime Medicine, Inc.

Security class: Common Stock
Shares / value: 16,080
Estimated value: $69,948
Report date: 01 Aug 2025
Price: $4.35
Ownership: Indirect

Form 4 holding Director

Vir Biotechnology, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 16,000
Estimated value: $24,480
Report date: 30 May 2024
Price: $1.53
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director, 10%+ Owner

Lyell Immunopharma, Inc.

Security class: Option (right to buy)
Shares / value: 130,000
Estimated value
Report date: 14 Jun 2024
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director, 10%+ Owner

Sana Biotechnology, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 80,000
Estimated value
Report date: 05 Jun 2025
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director, 10%+ Owner

Prime Medicine, Inc.

Security class: Stock Option (right to buy)
Shares / value: 45,000
Estimated value
Report date: 01 Aug 2025
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Denali Therapeutics Inc.

Security class: Stock Option (right to buy)
Shares / value: 6,222
Estimated value
Report date: 02 Jun 2021
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Denali Therapeutics Inc.

Security class: Restricted Stock Units
Shares / value: 0
Estimated value
Report date: 01 Jun 2021
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Robert Nelsen

4 PRME

Prime Medicine, Inc.

Report period: 01 Aug 2025
Transactions: 4
Transaction value: $0
Filing time: 05 Aug 2025, 20:43
Role: Director, 10%+ Owner
Next action: Open filing details

4 PRME

Prime Medicine, Inc.

Report period: 01 Aug 2025
Transactions: 1
Transaction value: +$9,999,990
Filing time: 01 Aug 2025, 19:19
Role: Director, 10%+ Owner
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 05 Jun 2025
Transactions: 1
Transaction value: $0
Filing time: 09 Jun 2025, 16:39
Role: Director, 10%+ Owner
Next action: Open filing details

4 PRME

Prime Medicine, Inc.

Report period: 04 Jun 2025
Transactions: 1
Transaction value: $0
Filing time: 05 Jun 2025, 18:13
Role: Director, 10%+ Owner
Next action: Open filing details

4 LYEL

Lyell Immunopharma, Inc.

Report period: 14 Jun 2024
Transactions: 1
Transaction value: $0
Filing time: 17 Jun 2024, 16:41
Role: Director, 10%+ Owner
Next action: Open filing details

4 PRME

Prime Medicine, Inc.

Report period: 12 Jun 2024
Transactions: 1
Transaction value: $0
Filing time: 14 Jun 2024, 16:59
Role: Director, 10%+ Owner
Next action: Open filing details

4/A SANA

Sana Biotechnology, Inc.

Report period: 06 Jun 2024
Transactions: 1
Transaction value: $0
Filing time: 15 Jul 2024, 16:12
Role: Director, 10%+ Owner
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 06 Jun 2024
Transactions: 1
Transaction value: $0
Filing time: 07 Jun 2024, 16:22
Role: Director, 10%+ Owner
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 30 May 2024
Transactions: 2
Transaction value: $0
Filing time: 03 Jun 2024, 12:14
Role: Director
Next action: Open filing details

4 PRME

Prime Medicine, Inc.

Report period: 15 Feb 2024
Transactions: 1
Transaction value: +$20,000,000
Filing time: 20 Feb 2024, 17:41
Role: Director, 10%+ Owner
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 08 Feb 2024
Transactions: 3
Transaction value: +$9,999,996
Filing time: 12 Feb 2024, 17:46
Role: Director, 10%+ Owner
Next action: Open filing details

4 LYEL

Lyell Immunopharma, Inc.

Report period: 08 Sep 2023
Transactions: 1
Transaction value: $0
Filing time: 08 Sep 2023, 16:24
Role: Director, 10%+ Owner
Next action: Open filing details

4 LYEL

Lyell Immunopharma, Inc.

Report period: 16 Jun 2023
Transactions: 1
Transaction value: $0
Filing time: 20 Jun 2023, 16:49
Role: Director, 10%+ Owner
Next action: Open filing details

4 PRME

Prime Medicine, Inc.

Report period: 14 Jun 2023
Transactions: 1
Transaction value: $0
Filing time: 16 Jun 2023, 17:49
Role: Director, 10%+ Owner
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 08 Jun 2023
Transactions: 1
Transaction value: $0
Filing time: 12 Jun 2023, 17:42
Role: Director, 10%+ Owner
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 22 May 2023
Transactions: 2
Transaction value: $0
Filing time: 24 May 2023, 16:16
Role: Director, 10%+ Owner
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 05 Jan 2023
Transactions: 1
Transaction value: $0
Filing time: 06 Jan 2023, 15:19
Role: Director, 10%+ Owner
Next action: Open filing details

4 PRME

Prime Medicine, Inc.

Report period: 24 Oct 2022
Transactions: 10
Transaction value: +$13,600,000
Filing time: 26 Oct 2022, 20:01
Role: Director, 10%+ Owner
Next action: Open filing details

3/A PRME

Prime Medicine, Inc.

Report period: 19 Oct 2022
Transactions: 0
Transaction value: $0
Filing time: 24 Oct 2022, 16:40
Role: Director, 10%+ Owner
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 05 Oct 2022
Transactions: 1
Transaction value: $0
Filing time: 06 Oct 2022, 16:06
Role: Director, 10%+ Owner
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 02 Sep 2022
Transactions: 8
Transaction value: $0
Filing time: 07 Sep 2022, 20:30
Role: Director, 10%+ Owner
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 30 Aug 2022
Transactions: 8
Transaction value: $0
Filing time: 01 Sep 2022, 17:22
Role: Director, 10%+ Owner
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 24 Aug 2022
Transactions: 8
Transaction value: $0
Filing time: 26 Aug 2022, 17:15
Role: Director, 10%+ Owner
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 18 Aug 2022
Transactions: 4
Transaction value: $0
Filing time: 22 Aug 2022, 17:15
Role: Director, 10%+ Owner
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 12 Aug 2022
Transactions: 12
Transaction value: $0
Filing time: 16 Aug 2022, 21:05
Role: Director, 10%+ Owner
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 05 Jul 2022
Transactions: 1
Transaction value: $0
Filing time: 07 Jul 2022, 16:30
Role: Director
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 08 Jun 2022
Transactions: 4
Transaction value: $0
Filing time: 10 Jun 2022, 21:24
Role: Director, 10%+ Owner
Next action: Open filing details

4 LYEL

Lyell Immunopharma, Inc.

Report period: 08 Jun 2022
Transactions: 1
Transaction value: $0
Filing time: 10 Jun 2022, 16:18
Role: Director, 10%+ Owner
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 06 Jun 2022
Transactions: 1
Transaction value: $0
Filing time: 08 Jun 2022, 18:31
Role: Director
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 02 Jun 2022
Transactions: 3
Transaction value: $0
Filing time: 06 Jun 2022, 20:25
Role: Director, 10%+ Owner
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 23 May 2022
Transactions: 2
Transaction value: $0
Filing time: 25 May 2022, 18:38
Role: Director, 10%+ Owner
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 05 Apr 2022
Transactions: 1
Transaction value: $0
Filing time: 06 Apr 2022, 17:54
Role: Director
Next action: Open filing details

4/A VIR

Vir Biotechnology, Inc.

Report period: 20 Dec 2021
Transactions: 1
Transaction value: $0
Filing time: 10 May 2022, 17:26
Role: Director, 10%+ Owner
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 29 Nov 2021
Transactions: 3
Transaction value: $0
Filing time: 01 Dec 2021, 17:31
Role: Director, 10%+ Owner
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 22 Nov 2021
Transactions: 3
Transaction value: $0
Filing time: 24 Nov 2021, 16:59
Role: Director, 10%+ Owner
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 01 Jul 2021
Transactions: 3
Transaction value: $0
Filing time: 06 Jul 2021, 16:48
Role: Director, 10%+ Owner
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 22 Jun 2021
Transactions: 3
Transaction value: $0
Filing time: 24 Jun 2021, 17:05
Role: Director, 10%+ Owner
Next action: Open filing details

4 LYEL

Lyell Immunopharma, Inc.

Report period: 21 Jun 2021
Transactions: 6
Transaction value: $0
Filing time: 23 Jun 2021, 17:38
Role: Director, 10%+ Owner
Next action: Open filing details

3 LYEL

Lyell Immunopharma, Inc.

Report period: 16 Jun 2021
Transactions: 0
Transaction value: $0
Filing time: 16 Jun 2021, 19:20
Role: Director, 10%+ Owner
Next action: Open filing details

4 DNLI

Denali Therapeutics Inc.

Report period: 02 Jun 2021
Transactions: 2
Transaction value: $0
Filing time: 04 Jun 2021, 18:35
Role: Director
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 21 May 2021
Transactions: 2
Transaction value: $0
Filing time: 25 May 2021, 16:44
Role: Director, 10%+ Owner
Next action: Open filing details

4 DNLI

Denali Therapeutics Inc.

Report period: 22 Mar 2021
Transactions: 6
Transaction value: $0
Filing time: 03 Jun 2021, 20:55
Role: Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .